Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.

Wang J, Wang J, Lopez E, Guo H, Zhang H, Liu Y, Chen Z, Huang S, Zhou S, Leeming A, Zhang RJ, Jung D, Shi H, Grundman H, Doakes D, Cui K, Jiang C, Ahmed M, Nomie K, Fang B, Wang M, Yao Y, Zhang L.

Blood Cancer J. 2019 Nov 28;9(12):95. doi: 10.1038/s41408-019-0259-8. No abstract available.

2.

PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.

Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, Rumball I, Cameron H, Hoang NM, Yang DT, Xu W, Zhang L, Wang M, Capitini CM, Rui L.

Leukemia. 2019 Dec;33(12):2898-2911. doi: 10.1038/s41375-019-0489-6. Epub 2019 May 23.

PMID:
31123343
3.

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.

Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M.

Sci Transl Med. 2019 May 8;11(491). pii: eaau1167. doi: 10.1126/scitranslmed.aau1167.

PMID:
31068440
4.

Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.

Ahmed M, Lorence E, Wang J, Jung D, Zhang L, Nomie K, Wang M.

Sci Signal. 2019 Feb 5;12(567). pii: eaat4105. doi: 10.1126/scisignal.aat4105. Review.

PMID:
30723172
5.

Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.

Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M.

Mol Cancer Ther. 2019 Feb;18(2):267-277. doi: 10.1158/1535-7163.MCT-18-0478. Epub 2018 Nov 9.

6.

Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.

Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie KJ, Zhang L, Wang M.

Oncogene. 2019 Mar;38(11):1802-1814. doi: 10.1038/s41388-018-0550-3. Epub 2018 Oct 25.

PMID:
30361685
7.

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.

Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML.

Br J Haematol. 2018 Nov;183(4):578-587. doi: 10.1111/bjh.15567. Epub 2018 Sep 2.

PMID:
30175400
8.

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.

Ye H, Desai A, Huang S, Jung D, Champlin R, Zeng D, Yan F, Nomie K, Romaguera J, Ahmed M, Wang ML.

J Exp Clin Cancer Res. 2018 Jul 13;37(1):150. doi: 10.1186/s13046-018-0800-9. Review.

9.

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.

Balaji S, Ahmed M, Lorence E, Yan F, Nomie K, Wang M.

J Hematol Oncol. 2018 Jun 15;11(1):83. doi: 10.1186/s13045-018-0621-5. Review.

10.

The B cell receptor signaling pathway in mantle cell lymphoma.

Merolle MI, Ahmed M, Nomie K, Wang ML.

Oncotarget. 2018 Mar 27;9(38):25332-25341. doi: 10.18632/oncotarget.25011. eCollection 2018 May 18. Review.

11.

Spontaneous regression of mantle cell lymphoma: a report of four cases.

Ye H, Desai A, Gong T, Zeng D, Nomie K, Chen W, Wang W, Romaguera J, Wang ML.

Cancer Commun (Lond). 2018 May 29;38(1):30. doi: 10.1186/s40880-018-0306-z.

12.

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.

Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M.

Clin Cancer Res. 2018 Aug 15;24(16):3967-3980. doi: 10.1158/1078-0432.CCR-17-3004. Epub 2018 Apr 17.

13.

No significant regulation of bicoid mRNA by Pumilio or Nanos in the early Drosophila embryo.

Wharton TH, Nomie KJ, Wharton RP.

PLoS One. 2018 Mar 30;13(3):e0194865. doi: 10.1371/journal.pone.0194865. eCollection 2018.

14.

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.

Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, Yao Y, Zeng D, Ahmed M, Nomie K, Zhang L, Wang M.

Blood Cancer J. 2018 Mar 20;8(3):33. doi: 10.1038/s41408-018-0066-7. No abstract available.

15.

Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma).

Zeng D, Desai A, Yan F, Gong T, Ye H, Ahmed M, Nomie K, Romaguera J, Champlin R, Li S, Wang M.

Am J Clin Oncol. 2019 Mar;42(3):304-316. doi: 10.1097/COC.0000000000000427. Review.

PMID:
29419530
16.

Smoldering mantle cell lymphoma.

Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, Wang ML.

J Exp Clin Cancer Res. 2017 Dec 15;36(1):185. doi: 10.1186/s13046-017-0652-8. Review.

17.

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.

Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L.

Blood Cancer J. 2017 Nov 23;7(12):632. doi: 10.1038/s41408-017-0005-z. No abstract available.

18.

Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity.

Liu Y, Yin Y, Zhang Z, Li CJ, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang ML, Zhao G.

Eur J Med Chem. 2017 Sep 29;138:543-551. doi: 10.1016/j.ejmech.2017.06.067. Epub 2017 Jun 30.

PMID:
28704757
19.

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.

Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M.

Oncologist. 2017 May;22(5):549-553. doi: 10.1634/theoncologist.2016-0328. Epub 2017 Apr 13.

20.

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

Srour SA, Lee HJ, Nomie K, Ye H, Chen W, Oriabure O, Romaguera J, Wang ML.

Br J Haematol. 2018 May;181(4):561-564. doi: 10.1111/bjh.14669. Epub 2017 Apr 2. No abstract available.

PMID:
28369820
21.

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.

Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M.

Clin Cancer Res. 2017 Aug 1;23(15):4212-4223. doi: 10.1158/1078-0432.CCR-16-2703. Epub 2017 Mar 27.

22.

ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma.

Ahmed M, Li L, Pinnix C, Dabaja B, Nomie K, Lam L, Wang M.

Crit Rev Oncol Hematol. 2016 Nov;107:14-19. doi: 10.1016/j.critrevonc.2016.08.008. Epub 2016 Aug 20. Review.

PMID:
27823642
23.

Gene mutations and actionable genetic lesions in mantle cell lymphoma.

Ahmed M, Zhang L, Nomie K, Lam L, Wang M.

Oncotarget. 2016 Sep 6;7(36):58638-58648. doi: 10.18632/oncotarget.10716. Review.

24.

Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.

Liu Y, Yin Y, Zhang J, Nomie K, Zhang L, Yang D, Wang ML, Zhao G.

Arch Pharm (Weinheim). 2016 May;349(5):356-62. doi: 10.1002/ardp.201500427. Epub 2016 Mar 18.

PMID:
26991997
25.

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L.

Lancet Oncol. 2016 Jan;17(1):48-56. doi: 10.1016/S1470-2045(15)00438-6. Epub 2015 Nov 28.

PMID:
26640039
26.

Nursing and Biobanking.

Sanner J, Yu E, Nomie K.

Adv Exp Med Biol. 2015;864:157-63. doi: 10.1007/978-3-319-20579-3_12.

PMID:
26420620
27.

The biobank at the University of Texas Health Science Center at Houston.

Sanner JE, Nomie KJ.

Biopreserv Biobank. 2015 Jun;13(3):224-5. doi: 10.1089/bio.2015.29004.jes. No abstract available.

28.

Novel and emerging strategies for longitudinal data collection.

Udtha M, Nomie K, Yu E, Sanner J.

J Nurs Scholarsh. 2015 Mar;47(2):152-60. doi: 10.1111/jnu.12116. Epub 2014 Dec 9. Review.

PMID:
25490868
29.

A missed connection: depression screening in cardiac inpatients.

Sanner JE, Gonzales S, Schultz K, Nomie K.

Nursing. 2014 Dec;44(12):60-5. doi: 10.1097/01.NURSE.0000451528.86974.ec. No abstract available.

PMID:
25406786
30.

The protection and stabilization of whole blood at room temperature.

Udtha M, Flores R, Sanner J, Nomie K, Backes E, Wilbers L, Caldwell J.

Biopreserv Biobank. 2014 Oct;12(5):332-6. doi: 10.1089/bio.2014.0026.

PMID:
25340942
31.

Tailless and Atrophin control Drosophila aggression by regulating neuropeptide signalling in the pars intercerebralis.

Davis SM, Thomas AL, Nomie KJ, Huang L, Dierick HA.

Nat Commun. 2014;5:3177. doi: 10.1038/ncomms4177.

PMID:
24495972
32.

Correction: A Versatile Method for Cell-Specific Profiling of Translated mRNAs in Drosophila.

Thomas A, Lee PJ, Dalton JE, Nomie KJ, Stoica L, Costa-Mattioli M, Chang P, Nuzhdin S, Arbeitman MN, Dierick HA.

PLoS One. 2013 Jul 24;8(7). doi: 10.1371/annotation/39194a57-4480-4f8e-b6fa-e7e0993d029b. Print 2013.

33.

A versatile method for cell-specific profiling of translated mRNAs in Drosophila.

Thomas A, Lee PJ, Dalton JE, Nomie KJ, Stoica L, Costa-Mattioli M, Chang P, Nuzhdin S, Arbeitman MN, Dierick HA.

PLoS One. 2012;7(7):e40276. doi: 10.1371/journal.pone.0040276. Epub 2012 Jul 6. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/39194a57-4480-4f8e-b6fa-e7e0993d029b.

Supplemental Content

Support Center